Publishing research using ab5644? Please let us know so that we can cite the reference in this datasheet.

ab5644 has been referenced in 19 publications.

  • Bashir AIJ  et al. A novel mechanism for the anticancer activity of aspirin and salicylates. Int J Oncol 54:1256-1270 (2019). PubMed: 30720135
  • Lee SK  et al. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab. Exp Mol Med 50:153 (2018). PubMed: 30459318
  • Wasén C  et al. Epidermal growth factor receptor function in the human urothelium. Int Urol Nephrol 50:647-656 (2018). WB, IHC-P . PubMed: 29508172
  • Ali A  et al. Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer. EMBO Mol Med N/A:N/A (2018). Human . PubMed: 29449326
  • Xue Z  et al. MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models. Cell Res 28:719-729 (2018). PubMed: 29795445
  • Laviolette LA  et al. Negative regulation of EGFR signalling by the human folliculin tumour suppressor protein. Nat Commun 8:15866 (2017). WB . PubMed: 28656962
  • Uchibori K  et al. Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat Commun 8:14768 (2017). WB . PubMed: 28287083
  • Iskit S  et al. Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer. Oncotarget 7:42859-42872 (2016). PubMed: 27374095
  • Bertotti A  et al. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature 526:263-7 (2015). PubMed: 26416732
  • McKee C  et al. Amphiregulin activates human hepatic stellate cells and is upregulated in non alcoholic steatohepatitis. Sci Rep 5:8812 (2015). WB . PubMed: 25744849
  • Raha D  et al. The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation. Cancer Res 74:3579-90 (2014). PubMed: 24812274
  • Greenfield E  et al. Registered report: Widespread potential for growth factor-driven resistance to anticancer kinase inhibitors. Elife 3:N/A (2014). PubMed: 25490934
  • Ather F  et al. Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab. PLoS One 8:e56112 (2013). WB ; Human . PubMed: 23405260
  • Wilson TR  et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487:505-9 (2012). Human . PubMed: 22763448
  • Deng M  et al. Effect and risk of AEE788, a dual tyrosine kinase inhibitor, on regeneration in a rat liver resection model. Eur Surg Res 44:82-95 (2010). WB ; Rat . PubMed: 20090347
  • Donovan MJ  et al. A systems pathology model for predicting overall survival in patients with refractory, advanced non-small-cell lung cancer treated with gefitinib. Eur J Cancer 45:1518-26 (2009). PubMed: 19272767
  • Franovic A  et al. Human cancers converge at the HIF-2alpha oncogenic axis. Proc Natl Acad Sci U S A 106:21306-11 (2009). WB ; Human . PubMed: 19955413
  • Rothenberg SM  et al. Modeling oncogene addiction using RNA interference. Proc Natl Acad Sci U S A 105:12480-4 (2008). WB ; Human . PubMed: 18711136
  • McDermott U  et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A 104:19936-41 (2007). PubMed: 18077425

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up